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Abstract
In human pathology, several diseases are associated with somatic mutations in the mitochondrial genome (mtDNA). Even
though mitochondrial dysfunction leads to increased oxidative stress, the role of mitochondrial mutations in atherosclerosis
has not received much attention so far. In this study we analyzed the association of mitochondrial genetic variation with the
severity of carotid atherosclerosis, as assessed by carotid intima-media thickness (cIMT) and the presence of coronary heart
disease (CHD) in 190 subjects from Moscow, Russia, a population with high CHD occurrence. cIMT was measured by high-
resolution B-mode ultrasonography and mtDNA heteroplasmies by a pyrosequencing-based method. We found that
heteroplasmies for several mutations in the mtDNA in leukocytes, including C3256T, T3336C, G12315A, G13513A, G14459A,
G14846A, and G15059A mutations, were significantly (p,0.001) associated with both the severity of carotid atherosclerosis
and the presence of CHD. These findings indicate that somatic mitochondrial mutations have a role in the development of
atherosclerosis.
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Introduction
In human pathology, several diseases have been associated with
somatic mutations in the mitochondrial genome. These mito-
chondrial mutations may arise during ontogenesis and are
associated with pathologies such as coronary vessel stenosis, some
forms of diabetes, myocardial infarction, cardiomyopathy and
other pathologies [1–17].
Atherosclerosis, the most common pathology in modern society,
is a multifactorial disease, in the development and progression of
which an interaction of phenotypic, environmental, socioeconomic
and genetic factors plays a significant role. Numerous polymor-
phisms of the nuclear genome, which are believed to be genetic
risk factors for atherosclerotic diseases, can help to explain for only
a few percentages of the variability of clinical manifestations of
atherosclerosis, such as coronary heart disease (CHD). At the same
time, mutations of the mitochondrial genome have remained out
of focus for a long time. However, they may play a pathogenic role
in the formation of atherosclerotic lesions of human arteries
causing various defects in the protein chains of some energy-
generating enzymes and transfer RNA (tRNA), synthesized
directly in the mitochondria. This leads to a decrease in the
concentration of these enzymes and their tRNA or total
dysfunction, which contributes to the development of oxidative
stress, deterioration of ATP production and accelerated develop-
ment of atherosclerosis.
In 2009, we developed a mutant allele quantitative assay to
study the differences in tissue-specific mitochondrial heteroplas-
mies [18]. Using this methodology we showed that there are
significant differences between unaffected intima and atheroscle-
rotic lipofibrous plaque in the level of heteroplasmy for several
point substitutions [18]. Further analysis revealed that several
mutations could be found in intimal cells that populate athero-
sclerotic lesions [19].
In a pilot study of ultrastructural characteristics of leukocytes
(Text File S1) we noted that in subjects without carotid
atherosclerosis, mitochondria typically contained well-defined
cristae, which were regularly located in the mitochondria matrix,
but the distribution and location of cristae in mitochondria in
leukocytes obtained from the blood of subjects with carotid
atherosclerosis were different (Fig. 1A–F). In some leukocytes
obtained from the blood of patients with carotid atherosclerosis
destructive alterations of mitochondria that were not present in
leukocytes of healthy subjects were observed (Fig. 2A–C). This
observation motivated us to investigate possible presence of
mutations in leukocytes in carotid atherosclerosis; The analysis
of mutation C3256T has revealed that there is a relation between
C3256T heteroplasmy level and predisposition to atherosclerosis
[20].
These findings motivated us to undertake the present study,
which was aimed to investigate if there might be association of the
levels of heteroplasmy of other mutations in leukocytes with the
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extent of carotid atherosclerosis as well as the presence of CHD. In
the present study a spectrum of well-known mutations, such as
A1555G, C3256T, T3336C, C5178A, G12315A, G13513A,
G14459A, G14846A, and G15059A, was analyzed.
Results
The phenomenon of heteroplasmy was observed for all
examined mutations of mitochondrial genome in the vast majority
of DNA samples, although the profiles of distribution differed
between mutations (Table 1). (In the present report, in order that
the levels of heteroplasmy among different mutations were visible,
we also included analysis of mutation C3256T, the data about
which was reported earlier [20]). The presence of mutation
A1555G was not detected only in one sample of 190, T3336C – in
3 samples, C5178A – in 6 samples, and G13513A – in 9 samples.
All other mutations were detected in all samples. Additionally,
100% of mutant allele was detected in DNA from blood leukocytes
only in one sample for T3336C, and in two samples for the
G15059A mutations.
We found significant correlations between carotid intima-media
thickness (cIMT) and the levels of heteroplasmy for C3256T
(r = 0.362, p,0.001), T3336C (r = 0.152, p = 0.036), G12315A
(r = 0.306, p,0.001), G13513A (r =20.357, p,0.001), and
G15059A (r = 0.316, p,0.001) mutations of the mitochondrial
genome (mtDNA). The levels of heteroplasmy for A1555G,
C5178A, G14459A, and G14846A had no associations with
cIMT. The data on the mean levels of heteroplasmy in the 1st and
4th quartiles of cIMT adjusted for age and gender are presented in
Table 2.
Additionally, the levels of heteroplasmy for mutations C3256T,
T3336C, G12315A, G13513A, G14459A, G14846A, and
G15059A correlated significantly with the size of atherosclerotic
plaques in any visualized segment of carotid arteries, as it was
evaluated by 4-point scale (Spearman’s Rho, 0.317, p,0.001,
0.328, p,0.001, 0.356, p,0.001, 20.492, p,0.001, 20.150,
p = 0.038, 20.153, p = 0.034, and 0.210, p = 0.003, respectively).
The levels of heteroplasmy for A1555G and C5178A did not
correlate with the size of atherosclerotic plaques. The data on the
mean levels of heteroplasmy in study participants without
atherosclerotic plaques and those participants who had an
atherosclerotic plaque in any visualized segment of carotid arteries
are shown in Table 2.
Of the conventional coronary risk factors, age had the strongest
association with the studied mtDNA heteroplasmies. Age corre-
lated with the level of heteroplasmy for C3256T (r = 0.279,
p,0.001), C5178A (r = 0.199, p = 0.006), G12315A (r = 0.255,
p,0.001), G13513A (r =20.363, p,0.001), G14459A
(r =20.192, p = 0.008), and G15059A (r = 0.328, p,0.001)
mutations of mitochondrial genome of circulating leukocytes.
For four of the nine mutations (C5178A, G1231A, G13513A and
G14459A) there was a difference between men and women (data
not shown). A significant correlation was also found between
systolic blood pressure and the G15059A heteroplasmy level
(r = 0.218, p = 0.002), and between triglycerides and T3336C
(r = 0.291, p,0.001) and G12315A (r = 0.153, p = 0.034) hetero-
plasmies. None of the studied heteroplasmies correlated with
either diastolic blood pressure, serum total cholesterol or LDL
cholesterol.
We have performed a regression analysis, in which the positive
or negative correlation was factored for deriving the association
between mtDNA mutations and atherosclerosis. The model
employing multiple regression caused serious problems, since the
number of variables that should be included for the construction of
a general model was too large for a given sample size. In this case,
a serious bias resulted in the loss of statistical significance for all
variables, both conventional risk factors and genetic markers.
Therefore, each mutation was tested separately for mediation/
moderation. For this purpose, paired regression model was
estimated (e.g., cIMT vs. mutation, or the presence/absence of
atherosclerotic plaque vs. mutation), and then the multiple
regression model was built, which also included conventional risk
factors, to avoid false correlations. For this analysis, cIMT and the
levels of heteroplasmy were taken as quantitative values (not
quartile or ranked values). Since cIMT was distributed normally,
the assumptions for linear regression analysis have been met. Two
models were compared to assess whether the inclusion of
mutations adds a significant contribution to the increase of
explanatory power for cIMT variability. The first model included
only conventional risk factors (age, gender, diabetes, hypertension,
triglycerides, LDL cholesterol, HDL cholesterol), and the second
model also included the levels of heteroplasmy for mtDNA
mutations. The residues in the second model were significantly
lower than those in in the model employing only conventional risk
factors (Fisher’s statistics 5.09, p,0.001). The model, which
included both conventional risk factors and mutations provided
significantly better explanatory level than the first one (adjusted
R2, 33.5% vs. 24.5%). The similar approach was used to assess
whether the inclusion of mutations adds a significant contribution
to the increase of explanatory power for diagnostics of the
presence of atherosclerotic plaque in any visualized segment of
carotids. In this case, binary logistic regression analysis was
performed, and a direct comparison of logit models was made
using chi-square statistic. Mutations provided statistically signifi-
cant information for diagnostics (p,0.001). So, in-depth statistical
analysis have supported our assumption on significant association
for atherosclerosis and CHD with heteroplasmy level of both
proatherogenic and atheroprotective mtDNA mutations.
It is notable that the levels of heteroplasmy for those mutations,
which were correlated significantly with cIMT and/or atheroscle-
rotic plaque size, also correlated between each other (Table 3). As
a rule, the levels of heteroplasmy positively correlated with carotid
atherosclerosis, were also directly associated with each other, but
correlated negatively with heteroplasmy levels of mutations, which
had a negative association with atherosclerosis. These correlations
suggested the presence of linkage disequilibrium; therefore, we
used one more measure of ‘‘integral mutation burden of
mitochondrial genome’’, which was calculated as a simple
arithmetic sum of quartile numbers (ranks) of heteroplasmy levels,
assigned from the analysis of heteroplasmy distribution within the
sample (interquartile borders are shown in Table 1). If hetero-
plasmy level was positively correlated with carotid atherosclerosis,
its quartile number was taken with positive sign, for negative
correlations – with negative sign. The measure of integral
mutation burden varied from 27 to 11, with a median value of
2. The integral mutation burden correlated significantly with both
cIMT (Spearman’s Rho, 0.376, p,0.001) and the size of
atherosclerotic plaque (Spearman’s Rho, 0.487, p,0.001).
The measure of ‘‘integral atherosclerotic burden’’ was also used
for analysis; it was calculated as a simple arithmetic sum of quartile
numbers of cIMT (adjusted for age and gender) and the score of
the size of atherosclerotic plaques in any visualized segment of
carotid arteries. Two measures, integral mutation burden and
integral atherosclerotic burden, also were correlated significantly
(Spearman’s Rho, 0.405, p,0.001). One-way analysis of variation
confirmed the strong relationship between these two measures
(F = 4.595, p,0.001).
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The ROC-curve analysis of sensitivity/specificity ratio was
performed to evaluate diagnostic significance of mutation burden
of mtDNA, when the presence of any atherosclerotic plaque in any
visualized carotid segment (Fig. 3-A), or the presence of CHD
(Fig. 3-B) were taken as actual states. Integral mutation burden
was calculated by using logistic regression model, which predicted
the probability of belonging to a particular category (the predictors
were the levels of heteroplasmy for C3256T, T3336C, G12315A,
G13513A, G14459A, G14846A, and G15059A mutations). For
the presence of atherosclerotic plaque, the area under curve
accounted for 0.78860.033, p,0.001 (95% confidence interval,
0.724–0.853). The cut-off value for integral mutation burden
accounted for 0.5558; under these conditions, the sensitivity of this
measure was 72.2%, and specificity was 70.2%. For the presence
of CHD, the area under curve accounted for 0.64860.050,
p = 0.003 (95% confidence interval, 0.549–0.746). The cut-off
value for integral mutation burden accounted for 0.5558; under
these conditions, the sensitivity of this measure was 62.2%, and
specificity was 63.9%.
The other kind of ROC-curve analysis, when integral mutation
burden calculated on the basis of quartile numbers of hetero-
plasmies distribution was taken as test variable, and the presence of
any atherosclerotic plaque in any visualized segment of carotid
arteries was taken as an actually observed state, has shown that the
area under curve accounted for 0.70760.038 (95% confidence
interval, 0.632–0.781). The cut-off value for integral mutation
burden accounted for 1.5; under these conditions, the sensitivity of
this measure was 63.0%, and specificity was 63.1%.
Figure 1. Different ultrastructural appearances of mitochondria in leukocytes obtained from healthy volunteers and patients with
carotid atherosclerosis (A–F). (A): A mitochondrion with well-defined cristae and well-preserved surrounding membranes typically seen in
leukocytes of healthy volunteers. (B–F): Mitochondria with reduced numbers of cristae and the oedema of the mitochondrial matrix observed in
patients with carotid atherosclerosis (A–F): Electron microscopy. Scales = 150 nm.
doi:10.1371/journal.pone.0068070.g001
Mutations of mtDNA and Carotid Atherosclerosis
PLOS ONE | www.plosone.org 3 July 2013 | Volume 8 | Issue 7 | e68070
The relationship between the levels of heteroplasmy of mtDNA
and the presence of CHD in study participants was also examined.
The results are presented in Table 2. The levels of heteroplasmy
for C3256T, T3336C, and G12315A were significantly higher,
and for G13513A and G14459A were significantly lower in CHD
patients as compared to study participants without clinical
manifestations of atherosclerosis. Seven CHD patients also had
the history of an acute myocardial infarction; the levels of
heteroplasmy for C3256T and G12315A mutations in them were
significantly higher as compared to the other study participants
(38.4%, SD 20.7, vs 22.7%, SD 14.2, p = 0.041, and 48.0%, SD
18.5, vs 32.1%, SD 19.3, p = 0.043).
In spite of relatively small sample size, statistical power in this
study reached 100% for the presence of carotid atherosclerotic
plaques in any visualized segment of carotid arteries, 89% for the
presence of CHD, and only 60% for the history of myocardial
infarction (all at a,0.05). This trend is easily explained by the fact
that clinical manifestations like CHD and myocardial infarction
should be considered as a probability function of the presence of
atherosclerosis itself, which is an obligatory prerequisite for
Figure 2. Ultrastructural appearances of mitochondria in leukocytes obtained from patients with carotid atherosclerosis (A–C). In
(A, B), note a profound focal oedema of the mitochondrial matrix and destructive alterations of cristae. In (C), a zone of destruction of the outer
mitochondrial membrane in shown by arrow (A–C): Electron microscopy. Scales = 150 nm.
doi:10.1371/journal.pone.0068070.g002
Table 1. Characteristics of distributions of heteroplasmy levels.
Mutation of mtDNA Heteroplasmy level, %
The proportion of cases
with identified mutation, %
range 25th percentile median 75th percentile mean (SD)
A1555G 0–83 10 13 18 16,5 (10.9) 99,5
C3256T 5–74 13 18 36 23.3 (14.7) 100
T3336C 0–100 5 7 10 8.3 (8.3) 98.4
C5178A 0–83 11 15 19 15.6 (10.6) 96.9
G12315A 2–88 18 28 51 32.3 (19.4) 100
G13513A 0–85 10 20 35 23.7 (18.7) 95.3
G14459A 3–82 12 18 33 27.2 (21.1) 100
G14846A 3–96 8 10 15 15.8 (17.4) 100
G15059A 4–100 26 39 47 37.6 (16.8) 100
doi:10.1371/journal.pone.0068070.t001
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clinically significant consequences. It may be speculated that in the
given time individuals already have subclinical atherosclerosis,
which is in part explained by mutations of mtDNA; to evaluate
prognostic significance of proatherogenic and atheroprotective
mtDNA mutations, long-tern prospective studies are needed. Our
data demonstrate that the presence of atherosclerosis and CHD is
associated significantly with integral mutation burden of mito-
chondrial genome. Therefore, the assessment of impact of single
mutation should be made on the basis of weighed coefficients
obtained from regression analysis. The thresholds for the level of
heteroplasmy for mutation to be in contention as a marker were
obtained from ROC-analysis. For G12315A it accounted for
26.5%; this value provided the sensitivity 0.704, and specificity
0,607; however, a range of values can be considered.
Discussion
Earlier we demonstrated a relation between C3256T and
predisposition to atherosclerosis [20]. This mutation is located in
coding sequence of the MT-TL1 gene (codon recognizing UUR)
which encodes tRNA leucine [21–23], and is expressed at the
cellular level as a reduced amount of cellular organelles and
impaired protein synthesis [21–23]. In this study we show for the
first time that at least six of other mitochondrial mutations
(T3336C, G12315A, G13513A, G14459A, G14846A, and
G15059A) are also associated with the extent of carotid
atherosclerosis, which was diagnosed in our study by means of
quantitative ultrasound examination of carotid arteries.
One of newly studied mutation, namely G12315A mutation
which can be expressed at the cellular level as a altered amount of
cellular organelles and impaired protein is located in the coding
sequence of mitochondrial gene encoding tRNA leucine, the MT-
TL2 gene (codon recognizing CUN). The results of this study
demonstrate that this mutation is associated with the extent of
atherosclerosis and even with its clinical manifestation CHD and,
possibly, myocardial infarction. Thus, the impairments of tRNA
leucine synthesis may act as a previously unknown mechanism for
atherosclerosis development and progression. By now, G12315A
mutation is described to be associated with mitochondrial
encephalomyopathy [8,24,25]. The association of this mutation
with atherosclerosis has not been reported previously. Another
studied mutation T3336C is located in the coding region of the
MT-ND1 gene encoding subunit 1 of NADH dehydrogenase;
however, it is considered to be a silent point mutation producing
no changes in protein sequence (ATT R ATC, Ile). We suggest,
however, that this mutation may be associated e.g. in linkage with
some mutant haplotype, still unknown, which produces human
pathologies. This assumption is partially supported by the high
correlation of heteroplasmy levels of T3336C and G12315A
mutations, the latter of which was strongly atherogenic in the
present data.
Mutations G13513A, G14459A, G14846A, and G15059A
occur in coding regions of genes responsible for the synthesis of
respiratory chain enzymes (MT-ND5 and MT-ND6 genes
encoding the subunits 5 and 6 of NADH dehydrogenase,
respectively, and MT-CYB gene encoding cytochrome B). An
impairment of NADH dehydrogenase activity can be expected to
attenuate NADH oxidation and CoQ (ubiquinone) reduction and
thus promote oxidative stress. Mutation G13513A (MT-ND5
gene) is believed to be associated with hereditary encephalomyo-
pathy, cardiomyopathy, and the WPW syndrome [25–28].
Mutation G14459A (MT-ND6 gene) results in alanine to valine
substitution in a conserved region of ND6 protein at position 72,
and is associated with hereditary ocular neuropathy, atrophy of
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visual nerve, Leber’s hereditary visual neuropathy, dysfunction of
basal ganglia, musculospastic syndrome and encephalopathy
[13,29–31]. Mutations G14846A and G15059A may lead to the
damage of cytochrome B: the first one results in glycine to serine
substitution in position 34, thus affecting intermediate transfer of
electrons in mitochondrial respiratory chains; the second one
results in glycine to stop codon substitution at position 190, thus
stopping translation and leading to the loss of 244 amino acids at
C-terminal of protein. Both mutations are capable of reducing
enzymatic function of cytochrome B, and associated with
mitochondrial myopathies [1,32,33].
The fact that none of the mutations examined in our study have
been yet associated with either atherosclerosis or CHD might be
due, in part, to methodological issues: the vast majority of the
existing nucleotide sequence analysis methods do not allow precise
quantitative measurement of heteroplasmies but indicate only the
presence of the mutant allele or provide semi-quantitative
assessment of proportion of mutant alleles in biological samples.
We demonstrated in the present study a high prevalence of
mutations of mitochondrial genome in a population sample, in
which the participants had no clinical signs of any mitochondrial
disease. Moreover, it is known nowadays that pathogenic
mitochondrial DNA mutations are very common in the general
population [34,35].Obviously, clinical and phenotypic manifesta-
tions should depend on the levels of heteroplasmies.
Surprisingly, high prevalence of mitochondrial mutations, as
well as rather high levels of heteroplasmies was found in this study;
it may be supposed that such phenomenon should have been
detected in the many hundreds of mtDNA genomes sequenced in
the past by Sanger sequencing for other purposes. However, direct
sequencing is not the method of choice for the quantitation of
heteroplasmy levels. As a rule, sequence analysis of heteroplasmy
around 50% provides clear results in terms of the presence of
heteroplasmy, but not in a quantitative manner. Lower level
heteroplasmy is often undetectable by direct sequencing. As an
example, Meierhofer et al. have used denaturing high perfor-
mance liquid chromatography to rapidly screen the entire mtDNA
for mutations; this approach yielded straightforward interpretation
of results with a detection limit down to 1% mtDNA hetero-
plasmy. However, direct sequencing analysis has become infor-
mative only after collection and re-amplification of low degree
heteroduplex peak-fractions [36]. Moreover, recently we have
performed full mtDNA sequencing using NGS approach (Roche’s
454 Sequencing technique) in 30 randomly selected persons. We
have detected 160 novel mutations of mtDNA, which have not
been described previously in numerous studies on direct mtDNA
sequencing; among them, 24 mutations were detected in 10–60%
cases, in which the heteroplasmy level varied from 7% to 64%
(preliminary data, not published). This finding provides one more
evidence that mitochondrial DNA mutations are much more
common in population, than could be expected from earlier
knowledge.
Mitochondrial mutations can be either somatic or inherited
through the maternal line. They are characterized by the
phenomenon of heteroplasmy, which is defined as the presence
of a mixture of more than one type of an organellar genome within
a cell or individual. Mitochondrial DNA is present in hundreds to
thousands of copies per cell and also has a very high mutation rate.
New mtDNA mutations arise in cells, coexist with wild-type
mtDNA, and segregate randomly during cell division. The high
prevalence of the examined mutations of mitochondrial genome
suggests that they are maternally inherited. On the other hand, the
heteroplasmy levels of six out of 10 mutations rose with increasing
age, which supports also the somatic nature of mutations: in any
case, there is an increase in the proportion of mutant alleles of the
mitochondrial genome of human white blood cells with age.
Although it appears likely, it is not known whether the processes of
accumulation of the mutant allele occur in other tissues of the
human body. Preferential survival of somatic cells or progenitor
cells with higher content of the mutant allele in the mitochondrial
DNA cannot be excluded either, although this assumption
contradicts the association of mitochondrial mutations with
neurodegenerative diseases and atherosclerosis, which reduce
longevity.
Leukocytes play a special role in atherogenesis [37]. They
migration of variety of leukocyte subtypes in the subendothelial
layer in arteries and their participation in the processes of
inflammation and atherosclerotic plaque formation is well
documented [38]. It is possible to expect that a high level of
mtDNA heteroplasmy in cells that circulate in the blood stream
might be indicative of a high likelihood that the defective
leukocytes with impaired mitochondrial function would enter into
the arterial intimal layer. If leukocyte function is inhibited due to
the presence of mutations in coding regions of mtDNA, this may
lead to local oxidative stress and other pathologic events which
could promote atherosclerosis formation. Thus one can assume
that mtDNA heteroplasmy, being a biomarker of defective
mitochondrial function in leukocytes, can also be regarded as a
biomarker for atherosclerosis and consequent clinical manifesta-
tions such as CHD.
The findings of the present investigation open prospects for
further studies. Even though the sample size in the present
investigation was sufficient to detect significant differences in the
levels of heteroplasmy of mitochondrial genome between non-
atherosclerotic participants and patients with subclinical athero-
sclerosis, or between CHD-free individuals and CHD patients, the
Table 3. Correlations between the levels of heteroplasmy of mitochondrial genome from human blood leukocytes.
Mutation Pearson’s correlation coefficient
T3336C G12315A G13513A G14459A G14846A G15059A
C3256T 0.303, p,0.001 0.792, p,0.001 20.626, p,0.001 20.435, p,0.001 20.153, p = 0.034 0.214, p = 0.003
T3336C – 0.412, p,0.001 NS NS NS NS
G12315A – 20.447, p,0.001 20.363, p,0.001 NS 0.212, p = 0.003
G13513A – 0.362, p,0.001 NS 20.238, p = 0.001
G14459A – 0.164, p = 0.023 NS
G14846A – 0.196, p = 0.006
doi:10.1371/journal.pone.0068070.t003
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results of this study may be needed to be extended by the use of
population sample taken not only from ethnically heterogeneous
population of Moscow that consisted of senior and elderly ages but
also from inhabitants of younger age. Obviously, other ethnic
groups should be studied as well. Finally, it is worth to noting here
that the present study was cross-sectional and thus the assessment
of actual risk of atherosclerosis and cardiovascular disease due to
the presence of mutations of mitochondrial genome requires
further prospective studies.
The findings of the study indicate that heteroplasmies for several
mutations in the mtDNA in leukocytes, including C3256T,
T3336C, G12315A, G13513A, G14459A, G14846A, and
G15059A mutations, are significantly (p,0.001) associated with
both the severity of carotid atherosclerosis and the presence of
CHD. These findings suggest that somatic mitochondrial muta-
tions might have a role in the development of atherosclerosis.
Materials and Methods
This study was kept in accordance with the Helsinki Declaration
of 1975 as revised in 1983. It was approved by the local ethics
committees of the Institute of General Pathology and Pathophys-
iology, Moscow, and Institute for Atherosclerosis Research,
Skolkovo Innovation Center, Moscow, Russia. All participants
gave their written informed consent prior to their inclusion in the
study.
The study participants were recruited consecutively from the
visitors flow at Moscow municipal outpatient clinics No. 202, who
have passed a routine screening for cardiovascular risk factors
(mainly blood cholesterol and arterial blood pressure). Exclusion
criteria were anatomic configuration of neck and carotid arteries
preventing from qualitative ultrasonography, serious life-threaten-
ing diseases, and the refusal from signing informed consent form.
In total, 190 participants were recruited (84 men, 106 women)
aged 65.0 years (SD 9.4); among them 45 participants (24%) had
clinical CHD. The gender ratio was similar in healthy participants
and CHD patients (P = 0.17). CHD patient were older than
healthy participants; mean age was 70.0 (SD 8.7) and 63.5 (SD
9.0), respectively, P,0.001. Antropometric, clinical and biochem-
ical characteristics of study participants are given in Table 4.
High-resolution B-mode ultrasonography was used for carotid
arterial imaging to assess the extent of carotid atherosclerosis. The
protocol of ultrasound examination involved the scanning of the
right and left common carotid artery and the area of the carotid
sinus (bulb) as high up as possible [39]. Three fixed angles of
interrogation were used (anterolateral, lateral, and posterolateral).
Images were focused on the posterior wall of the artery. The B-
mode ultrasound system (SSI-1000, SonoScape, China) used a
7.5 MHz linear array probe. The measurements were always
performed at 10-mm section of common carotid artery adjacent to
the carotid bulb. The carotid intima-media thickness (cIMT) of the
posterior wall was measured as the distance from the leading edge
of the first echogenic (bright) line to the leading edge of the second
echogenic line. The measurements were carried out with M’Ath
computer software (IMT, France). The mean of three measure-
ments (in anterolateral, lateral, and posterolateral positions) was
considered to be the integral cIMT estimate. Reproducibility of
cIMT measurements was assessed according to the protocol of the
IMPROVE Study [40].
The degree of susceptibility to atherosclerosis was estimated by
using interquartile cIMT values derived from Moscow population
sample of 1287 participants (429 men, 858 women) free of CHD
(Table 5). Such approach allowed distinguishing persons predis-
posed or not predisposed to atherosclerosis. If a person belonged to
the lowest quartile of age-adjusted cIMT distribution, this person
was considered as non-predisposed to atherosclerosis; if the person
belonged to the highest quartile, then this person had a high
predisposition to atherosclerosis. The belonging to the 2nd or the
3rd quartiles of cIMT distribution was regarded as a moderate or
elevated susceptibility, respectively.
Figure 3. ROC-curves for analysis of sensitivity/specificity ratio
to evaluate diagnostic significance of integral mutation
burden of mtDNA, when the presence of any atherosclerotic
plaque in any visualized carotid segment (A), or the presence
of CHD (B) are taken as actual states. Integral mutation burden is
calculated by using logistic regression model, which predicted the
probability of belonging to a particular category (the predictors are the
levels of heteroplasmy for C3256T, T3336C, G12315A, G13513A,
G14459A, G14846A, and G15059A mutations).
doi:10.1371/journal.pone.0068070.g003
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Additionally, the presence and the size of atherosclerotic
plaques in any visualized segment of carotid arteries was evaluated
by a 4-point scale (0 - no atherosclerotic lesions; 1–2 - elevated
atherosclerotic plaques taking up to 20% or 20 to 50% of lumen
diameter, respectively: 3 - hemodynamically significant athero-
sclerotic plaques taking more than 50% of lumen diameter).
DNA samples were obtained from whole venous blood using a
commercially available kit for DNA purification (QIAGEN
GmbH, Germany). For the amplification of fragments of
mitochondrial DNA by polymerase chain reaction (PCR) method
followed by pyrosequencing, the previously described primers and
conditions were used [18]. In brief, to quantitatively evaluate
mutant allele, a method of pyrosequencing [41–43] was adapted
for conditions where both normal and mutant alleles were present
in a biological specimen; the defective allele was quantified by
analyzing the peak heights in the pyrogram of one-chained PCR-
fragments of a mitochondrial genome. The levels of heteroplasmy
in DNA samples were calculated, taking into account the expected
sequence and the dimension of peaks for the homozygotes
possessing either 100% of the normal or 100% of the mutant
allele, as described elsewhere [18]. The nucleotide sequences for
forward primers, reverse primers, and sequence primers are
represented in Table 6.
Within this study, a total of 43 mutations of mtDNA have been
tested (A1555G, A3280G, A750G, C14482C, C14482G,
C15452A, C3256T, C3285T, C5178A, C6489A, G12351A,
G13513A, G14459A, G14846A, G15059A, G15084A,
G15762A, G3316A, G5540A, G8363A, G3316A, G9379A,
T14484C, T14487C, T14709C, T3258C, T3271C, T3336C,
T5692C, T5814C, T716G, T8362G, T8993C, T8993G, inser-
tions ins5132AA, ins652G, ins961C, and deletions del15498_23,
del5132AA, del652G, del9489, del9537C, del961C). As a result,
Table 4. Antropometric, clinical and biochemical characteristics of study participants.
Variable Total group, n=190 Non-CHD controls, n = 145 CHD patients, n = 45 P for the difference
Age, years 65.0 (9.4) 63.5 (9.0) 70.0 (8.7) ,0.001 *
Gender, m:f 84:106 60:85 24:21 NS (0.10)
BMI, kg/m2 26.9 (4.6) 26.6 (4.5) 27.7 (4.8) NS (0.10) **
SBP, mm Hg 139 (17) 138 (17) 141 (18) NS *
DBP, mm Hg 83 (11) 83 (10) 81 (13) NS ***
Smokers, % 8.9 11.0 2.2 NS (0.06)
Hypertension, % 64.9 58.9 84.4 0.001
LVH, % 34.0 28.1 53.3 0.002
Diabetes, % 12.6 6.8 31.1 ,0.001
Angina, % 24.1 0.0 100.0 ,0.001
AMI in anamnesis, % 3.7 0.0 15.6 ,0.001
Stroke in anamnesis, % 2.6 0.0 8.9 0.011
Family anamnesis for AMI, % 27.7 26.0 33.3 NS
Family anamnesis for HT, % 39.3 39.0 40.0 NS
Family anamnesis for T2DM, % 17.3 17.1 17.8 NS
Total cholesterol, mg/dl 239 (48) 240 (48) 235 (50) NS *
Triglycerides, mg/dl 127 (60) 125 (60) 131 (60) NS **
LDL cholesterol, mg/dl 148 (43) 148 (43) 145 (45) NS *
HDL cholesterol, mg/dl 66 (15) 67 (15) 63 (16) NS *
Fasting blood glucose, mmol/l 4.9 (1.2) 4.8 (1.2) 5.2 (1.6) NS *
Statins, % 11.5 7.5 24.4 0.006
Plaque, score 0.83 (0.86) 0.73 (0.85) 1.16 (0.85) 0.003 **
Mean cIMT, mm 869 (167) 841 (150) 961 (189) ,0.001 *
Maximum cIMT, mm 1006 (213) 971 (185) 1117 (258) ,0.001 **
*one-way ANOVA;
**Mann-Whitney U-test;
***Welch test.
doi:10.1371/journal.pone.0068070.t004
Table 5. Interquartile cIMT values derived from Moscow
population.
Age
,50 51–60 61–70 .70
Men
2nd quartile, mm 660 740 830 840
3rd quartile, mm 745 810 910 930
4th quartile, mm 800 910 990 1060
Women
2nd quartile, mm 605 665 760 825
3rd quartile, mm 665 735 830 895
4th quartile, mm 740 815 920 990
doi:10.1371/journal.pone.0068070.t005
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most of mutations were excluded from further analysis, as they
were not found in DNA from leukocytes, or have demonstrated a
negligibly low level of heteroplasmy (1–5%). Mutations C3256T,
T3336C, G1231A, G13513A, G14459A, G14846A and G15059A
were found to have high prevalence in the study sample, and
demonstrated high variability; therefore, they were selected for
further analysis. The results on C3256T heteroplasmy seemed to
have the highest diagnostic significance; therefore, we have
analyzed and reported the data on C3256T separately [20].
However, during in-depth analysis several mutations proved to be
associated in some way either with cIMT, or CHD, or the
presence of atherosclerotic plaques. Thus, the role of integral
mutation burden of mtDNA in predisposition to atherosclerosis or
its clinical manifestations has been analyzed, and within this
analysis, C3256T heteroplasmy was included as one of the factors
responsible for formation of integral mutation burden.
As the validity of the heteroplasmy measurements seemed to be
crucial, and pyrosequencing method is not so common and self-
explanatory for the reader, an experimental proof with the
introduction of different proportion of a mutated allele was
obtained. Theoretical background for calculation of heteroplasmy
level by analyzing the peak heights in the pyrogram, as well as
original peak height histograms of real samples were described
elsewhere [18]. To get the data on pyrosequencing calibration, the
mixtures of DNA samples with either 100% of the normal or
100% of the mutant allele were tested, with the ratio of 1:0
(homoplasmy), 4:1 (20% heteroplasmy), 2:3 (40% heteroplasmy),
1:2 (67% heteroplasmy), and 0:1 (homopasmy). To estimate the
reproducibility of measurements, this set of DNA mixtures was
analyzed in 6 independent experiments. The original pyrograms
are shown at Figure S1. The results of measurements were very
close to the expected values, and accounted for 0%, 18%, 42%,
66%, and 100%. The data on reproducibility of measurements are
given in Table S1. The mean value of coefficient of variation for
20%, 40% and 67% heteroplasmic mixtures accounted for 4.7%,
and for 100% mutant allele –2.1%; in the opposite, for 100%
normal allele small erroneous peaks for mutant nucleotide were
detected, which provided a coefficient of variation of 35.1%
(Figure S2). These observations allowed us to conclude that for
determining the level of heteroplasmy higher than 10%, the
coefficient of variation does not exceed 10%, and the results of
quantitative heteroplasmy measurements are accurate and repro-
ducible. However, for very low heteroplasmy levels (less than 5%),
this method is effective for the assessment of the presence of
heteroplasmy, but does not provide precise measurements. On the
other hand, such low heteroplasmy levels will hardly result in
clinical consequences. Based on this assumption, the heteroplasmy
levels below 5% were considered negligible.
To demonstrate the variability in heteroplasmy levels in real
DNA samples, several original pyrograms are presented in Figure
S3.
Statistical analysis was performed using the SPSS 14.0 software
(SPSS Inc., USA). The methods of one-way analysis of variance,
cross-tabulation analysis, and correlation analysis by Spearman
and Pearson were used. The comparison of mean values for
continuous variables was performed using the U-test by Mann-
Whitney, for categorical variables by chi-square Pearson’s test.
The data are presented in terms of mean and SD. The significance
of differences was defined at the 0.05 level of confidence.
Supporting Information
Figure S1 Pyrograms of the mixtures of DNA samples with the
ratio of normal and mutant allele 1:0 (homoplasmy, 0% mutant
allele), 4:1 (20% heteroplasmy), 2:3 (40% heteroplasmy), 1:2 (67%
heteroplasmy), and 0:1 (homopasmy, 100% mutant allele).
(TIF)
Figure S2 Graph showing the relationship between the level of
heteroplasmy in mixed DNA samples and coefficient of variation
of measurements.
(TIF)
Figure S3 Practical pyrograms for the measurement of mtDNA
heteroplasmy levels. Upper row, C3256T heteroplasmy; left –4%
heteroplasmy, right –13% heteroplasmy. Middle row, G12315A
heteroplasmy; left –0% heteroplasmy, right –83% heteroplasmy.
Lower row, G13513A heteroplasmy; left –4% heteroplasmy, right
–74% heteroplasmy.
(TIF)
Table S1 The descriptive statistics and analysis of reproducibil-
ity of heteroplasmy level measurements by pyrosequensing method
in DNA mixtures.
(DOCX)
Text File S1 TEM procedures. For electron microscopic
analysis, samples of white blood cells were processed according to
the procedures described by James et al [1]. As a fixative, 1.5%
glutaraldehyde in 0.1 M phosphate buffer (pH 7.2) was used; for
post-fixation 1% OsO4 was used. White blood cells were
embedded in Araldite resin. Ultrathin sections were stained with
uranyl acetate and lead citrate and examined with the aid of a
Hitachi H7000 electron microscope at an accelerating voltage of
Table 6. Primers for PCR and pyrosequencing.
Mutation Forward primer for PCR Reverse primer for PCR Sequence primer
G1555A TAGGTCAAGGTGTAGCCCATGAGGTGGCAA bio-GTAAGGTGGAGTGGGTTTGGG ACGCATTTATATAGAGGA
C3256T bio-AGGACAAGAGAAATAAGGCC ACGTTGGGGCCTTTGCGTAG AAGAAGAGGAATTGA
T3336C bio-AGGACAAGAGAAATAAGGCC ACGTTGGGGCCTTTGCGTAG TGCGATTAGAATGGGTAC
C5178A bio-GCAGTTGAGGTGGATTAAAC GGAGTAGATTAGGCGTAGGTAG ATTAAGGGTGTTAGTCATGT
G12315A bio-CTCATGCCCCCATGTCTAA TTACTTTTATTTGGAGTTGCAC TTTGGAGTTGCAC
G13513A CCTCACAGGTTTCTACTCCAAA bio-AAGTCCTAGGAAAGTGACAGCGAGG AGGTTTCTACTCCAA
G14459A CAGCTTCCTACACTATTAAAGT bio-GTTTTTTTAATTTATTTAGGGGG GATACTCCTCAATAGCCA
G14846A CAGCTTCCTACACTATTAAAGT bio-GTTTTTTTAATTTATTTAGGGGG GCGCCAAGGAGTGA
G15059A CAGCTTCCTACACTATTAAAGT bio-GTTTTTTTAATTTATTTAGGGGG TTTCTGAGTAGAGAAATGAT
doi:10.1371/journal.pone.0068070.t006
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75 kV. 1. James V, Winfield DA, James N (1988) Ultrastructural
features of acute monoblastic leukaemia cells: a multivariate
morphometric analysis. Virchows Arch A Pathol Anat Histopathol
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